2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-137440
    Firazorexton 2274802-95-6 99.94%
    Firazorexton (TAK-994 free base) is an orally active and brain-penetrant orexin type 2 receptor (OX2R) selective agonist. Firazorexton (TAK-994 free base) can promote wakefulness and has the potential to improve narcolepsy-like symptoms in mice.
    Firazorexton
  • HY-139196
    ThioLox 1202193-89-2 99.97%
    ThioLox is a competitive 15-lipoxygenase-1 (15-LOX-1) inhibitor with a Ki of 3.30 μM. ThioLox shows anti-inflammatory and neuroprotective properties.
    ThioLox
  • HY-144377
    RXR antagonist 1 3010910-40-1 99.94%
    RXR antagonist 1 (compound 6a) is a retinoid X receptor (RXR) modulator. RXR antagonist 1 shows potent RXR-antagonistic activity, with a pA2 of 8.06. RXR antagonist 1 can be used for type 2 diabetes research.
    RXR antagonist 1
  • HY-144765
    NF-κB-IN-4 99.66%
    NF-κB-IN-4 (compound 17) is a potent and BBB-penetrated NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research.
    NF-κB-IN-4
  • HY-145429
    IL-17A modulator-2 2748749-47-3 98.44%
    IL-17A modulator-2 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 27. IL-17A modulator-2 inhibits the biological action of IL-17A with a pIC50 of 8.3. IL-17A modulator-2 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders.
    IL-17A modulator-2
  • HY-148650
    Sortilin antagonist 1 2691846-93-0 99.63%
    Sortilin antagonist 1 (compound 44) is a sortilin antagonist with an IC50 value of 20 nM for inhibiting Neurotensin (NTS) binds to sortilin. Neurotensin is a sortilin ligand. Sortilin antagonist 1 can be used for the research of neurological disease.
    Sortilin antagonist 1
  • HY-148822
    Nampt activator-2 2237268-90-3 98.80%
    Nampt activator-2 (compound 34) is a potent NAMPT activator, with EC50 of 0.023 μM. Nampt activator-2 shows moderate activity against CYP2C9 (0.060 μM), 2D6 (0.41 μM) and 2C19 (0.59 μM).
    Nampt activator-2
  • HY-151412
    T-271 1005775-58-5 99.97%
    T-271 is a selective inducer of mitochondrial autophagy.
    T-271
  • HY-152026
    NADPH oxidase-IN-1 2762405-17-2 99.60%
    NADPH oxidase-IN-1 is an orally active NADPH oxidase (Nox) inhibitor, related with neuronal inflammation. NADPH oxidase-IN-1 can cross the blood-brain barrier (BBB), inhibits Nox2 and Nox4 with IC50s of 1.9 μM and 2.47 μM, respectively. NADPH oxidase-IN-1 suppresses pro-inflammatory cytokines production and LPS-mediated microglial migration, also has in vivo efficacy.
    NADPH oxidase-IN-1
  • HY-153019
    NUCC-0000323 663212-78-0 99.85%
    NUCC-0000323 is a potent superoxide dismutase 1 (SOD1) inhibitor. NUCC-0000323 inhibits SOD1 expression. NUCC-0000323 can be used in research of amyotrophic lateral sclerosis (ALS).
    NUCC-0000323
  • HY-153686
    BVFP 357158-20-4 98.12%
    BVFP binds to the PGRN588–593 peptide with a Kd of 20 μM. BVFP can disrupt PGRN-SORT1 binding. BVFP also inhibits SORT1-mediated rPGRN endocytosis.
    BVFP
  • HY-156684
    Nedizantrep 2376824-99-4 99.77%
    GDC-6599 is an orally active TRPA1 inhibitor, with IC50 values of 5.3 nM in humans, 6.6 nM in rats, 9.3 nM in dogs, 7.2 nM in monkeys, and 15 nM in guinea pigs. GDC-6599 can be used in the research of neuropathic pain and respiratory diseases such as asthma and chronic cough.
    Nedizantrep
  • HY-157784
    XPC-7724
    XPC-7724 is a selective Nav1.6 channel inhibitor with a IC50 value of 0.078 μM. XPC-7724 can be used in the study of neurological diseases.
    XPC-7724
  • HY-161246
    uPSEM792 2323525-19-3 99.92%
    uPSEM792 is a pharmacologically selective effector molecules (PSEM) agonist for PSAM4-GlyR, with an affinity of Ki of 0.7 nM. uPSEM792 is a substrate for efflux transporters in brains of wild type and dual P-gp and BCRP knockout mice. uPSEM7952 is a possible lead for developing the PET radioligand for PSAM4-GlyR.
    uPSEM792
  • HY-17038A
    Agomelatine hydrochloride 1176316-99-6 99.98%
    Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine hydrochloride is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively.
    Agomelatine hydrochloride
  • HY-B0914A
    10-Undecenoic acid zinc salt 557-08-4 ≥98.0%
    10-Undecenoic acid zinc salt (Undecylenic acid zinc salt) is an antifungal agent. 10-Undecenoic acid zinc salt inhibits Aβ oligomerization, scavenges ROS and inhibits μ-calpain activity. 10-Undecenoic acid zinc salt has neuroprotective effects. 10-Undecenoic acid zinc salt has anticancer effects on a variety of tumors. 10-Undecenoic acid zinc salt inhibits C. albicans biofilm formation and MRSA infection. 10-Undecenoic acid zinc salt inhibits quorum sensing signals of Bacillus subtilis and Pseudomonas aeruginosa.
    10-Undecenoic acid zinc salt
  • HY-D1024A
    Coelenterazine h hydrochloride 98.80%
    Coelenterazine h (2-Deoxycoelenterazine) hydrochloride, a coelenterazine derivative, is a luminescent substrate for RLuc8. Coelenterazine h hydrochloride is more sensitive to Ca2+, thus providing a valuable tool for measuring small changes in Ca2+ concentrations.
    Coelenterazine h hydrochloride
  • HY-N0814A
    Phytic acid dodecasodium hydrate 123408-98-0 ≥98.0%
    Phytic acid (Inositol hexaphosphate) dodecasodium hydrate is a phosphorus storage compound of seeds and cereal grains. Phytic acid dodecasodium hydrate is known as a food inhibitor, which has a strong ability to chelate multivalent metal ions, specially zinc, calcium, iron and as with protein residue. Phytic acid dodecasodium hydrate inhibits the enzymatic superoxide source xanthine oxidase (XO), and has antioxidative, neuroprotective, anti-inflammatory effects.
    Phytic acid dodecasodium hydrate
  • HY-P1298A
    Sauvagine TFA 98.76%
    Sauvagine TFA, a 40-amino-acid neuropeptide from the skin of the frog, is a mammalian CRF agonist. Sauvagine TFA is effective at releasing ACTH from rat pituitary cells. Sauvagine TFA possesses a number of pharmacological actions on diuresis, the cardiovascular system and endocrine glands.
    Sauvagine TFA
  • HY-P1501A
    δ-Sleep Inducing Peptide acetate 99.84%
    δ-Sleep Inducing Peptide acetate is a neuropeptide, with antioxidant and anxiolytic properties.
    δ-Sleep Inducing Peptide acetate
Cat. No. Product Name / Synonyms Application Reactivity